Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ReFacto AF in PTPs With Severe Hemophilia A
NCT00037544Phase 3Completed
- Sponsor
- Pfizer
- Primary completion
- Aug 2004
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of moroctocog alfa in hemophilia A, sponsored by Pfizer. Primary endpoints: Neoantigenicity (Inhibitor Formation), Efficacy in Treating Acute Bleeding Episodes and 1 more. Status: completed.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00037544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037544.